Latent Tuberculosis Diagnosis and Management

Thursday, October 27, 2016: 12:30 PM-2:00 PM

Room: Poster Hall

Learning Objectives:

Tracks: Adult ID

Presentations:

526

Low Uptake of Treatment for Latent TB in an Outbreak Affecting an Island
Niamh Allen, MB, BCh, DTMH ; Catherine Fleming, MB, MPH, FRCPI ; Diarmuid O'donovan, MD, FFPHMI ; Anthony O'regan, MD, FRCPI ; Cathy Higgins, MB, MPH, LFOM

527

Comparison of Predictors of Indeterminate QuantiFERON-TB Gold In-Tube Test Results between Inpatients and Outpatients
Katerina Oikonomou, MD, PhD ; Panagiotis Vlachostergios, MD, PhD ; William Pagano, MD ; Carla Sue Mcwilliams, MD ; Jeanne Carey, MD

Posters

Quantiferon in Inpatients and Outpatients ID Week 2016.pdf (484.3 kB)

528

Use of Shortened Regimen for the Treatment of Latent Tuberculosis Infection in Patients of the Veterans Affairs Healthcare System—2012–2015.
Sapna Morris, MD, MBA ; Nwabunie Nwana, MPH ; Patricia Schirmer, MD ; Wendy Thanassi, MA, MD ; Roger Bedimo, MD ; Cynthia Lucero-Obusan, MD ; David Yost, MD, Msc

529

Latent Tuberculosis Infection Screening among HIV-Infected Patients: Tuberculin Skin Test vs. Interferon-Gamma Release Assay
Joella Adams, MPH ; Ashley Andrews, MPH ; Chanelle Howe, PhD ; Christopher Vinnard, MD

Posters

LTBI Poster 10-12-2016.pdf (212.5 kB)

530

Risk Factors for Missed Study Visits Among Patients with a Positive Screening Test for Latent Tuberculosis Infection (LTBI)
Marian Lacy, MD ; Fernanda Maruri, MPH ; Kristian Atchley, RN, BSN ; Timothy R. Sterling, MD, FIDSA ; April Pettit, MD, MPH

531

Adoption of a Twelve Week Isoniazid/Rifapentine Regimen for the Treatment of Latent Tuberculosis Infection in a Federal Healthcare System: Indian Health Service.
David Yost, MD, Msc ; Sapna Morris, MD, MBA ; Nwabunie Nwana, MPH ; Michael Bartholomew, MD

532

Usefulness of simultaneous performance of an IGRA and TST for latent tuberculosis screening in rheumatology patients. Influence of disease and treatment
Paloma Gijón, MD/PhD ; Patricia Muñoz, MD/PhD ; María Jesús Ruiz-Serrano, Pharm ; María Montoro, MD/PhD ; Martha Kestler, MD/PhD ; Oihane Aldecoa-Otarola, MD ; Emilio Bouza, MD, PhD

Posters

Slide1.PNG (3.1 MB)

533

Feasibility of Using Video Visits for Direct Observation of Treatment of Latent Tuberculosis with Twelve Weekly Doses of Isoniazid and Rifapentine
Deborah Gold, MD ; Warren Choy, MD ; C. Bradley Hare, MD

Posters

160500_poster_v4_Gold.pdf (148.4 kB)

534

Vitamin D Deficiency and Latent Tuberculosis Infection Risk among Tuberculosis Household Contacts.
María Elvira Balcells, MD, MSc ; Patricia García, MD ; Camila Tiznado, BSc ; Luis Villarroel, PhD ; Natalia Scioscia, BSc ; Camila Carvajal, RN ; Francesca Zegna-Ratá, RN ; Carlos Peña, MD ; Rodrigo Naves, PhD

Posters

poster ID week oct 2016.jpg (869.3 kB)

535

Public Health Department Contact Investigation and Directly Observed Prophylactic Therapy Enhance Completion of Latent Tuberculosis Infection (LTBI) Therapy in Children Compared with Adults
Emily Souder, MD ; Jennifer Vodzak, MD ; Sarah S. Long, MD ; Christina Dogbey, MPH ; Jane M. Gould, MD

536

Completion Rate and Safety of Twelve Weekly Doses of Directly Observed Isoniazid and Rifapentine for Latent Tuberculosis Infection
Tracey Sweeney, Pharm.D. ; John Ahern, Pharm.D. ; W. Kemper Alston, MD, MPH

Posters

IDWeek_Poster_Submission_PDF.pdf (309.0 kB)

CME Credits: No CME credit is offered for this session.

ACPE Credits:

ACPE Number:

See more of: Poster Abstract Session